| 产品描述: | VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity |
| 靶点: |
Ki: 104 pM (Menin-MLL interaction);Apoptosis; EpigeneticReaderDomain; HistoneMethyltransferase |
| 体外研究: |
VTP50469 在携带 (MOLM13 (IC50: 13 nM)、THP1 (IC50: 37 nM),NOMO1 (IC50: 30 nM),ML2 (IC50 为 16 nM),EOL1 (IC50 为 20 nM),以及小鼠 MLL-AF9 细胞 (IC50 为 15 nM) 和 ALL (KOPN8 (IC50 为 15 nM),HB11;19 (IC36 nM 的 50)、MV4;11 (17 nM 的 IC50)、SEMK2 (27 nM 的 IC50) 和 RS4;11 (IC 50: 25 nM)) 。 在早期时间点, MLL-r B 细胞以剂量依赖性方式响应 VTP50469 发生细胞凋亡。MLL-r AML 细胞系在暴露于 VTP50469 后 4-6 天开始经历剂量依赖性分化。 VTP50469 将 Menin 从蛋白质复合物中置换出来,并抑制 MLL 的染色质占据基因。MLL 结合的丧失导致基因表达、分化和细胞凋亡发生变化 |
| 体内研究: |
VTP50469 (15-60 mg/kg;口服;每天两次;28 天;NSG 小鼠) 处理在所有剂量水平上都非常有效,并且所有处理组都具有显著的生存优势。以 30 和 60 mg/kg VTP50469 给药的小鼠可延长生存优势。 Animal Model: Unconditioned immunodeficient (NSG) mice with MV4;11 cells Dosage: 15 mg/kg, 30 mg/kg, and 60 mg/kg Administration: Oral administration; twice a day; for 28 days Result: Was highly efficacious across all dosage levels and all treatment groups had a significant survival advantage over the control group. |
| 参考文献: |
1. Krivtsov AV, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019 Dec 9;36(6):660-673.e11. 2. Andrei V. Krivtsov, et al. Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia. Cancer Resceach. July 2018.Volume 78, Issue 13 Supplement. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.585 ml |
7.926 ml |
15.852 ml |
| 5 mM |
0.317 ml |
1.585 ml |
3.17 ml |
| 10 mM |
0.159 ml |
0.793 ml |
1.585 ml |
| 50 mM |
0.032 ml |
0.159 ml |
0.317 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |